EMA Recommends Susvimo Implant for Wet AMD
EMA recommends Susvimo for nAMD as a refillable ocular implant that releases ranibizumab over time. On 24 July 2026 the CHMP backed EU authorisation for adults with stable neovascular age-related macular degeneration after they have already responded to intravitreal anti-VEGF therapy.
Contents10 sections
Key Takeaways
- CHMP recommended Susvimo (ranibizumab) with a surgically placed refillable implant for stable nAMD after prior anti-VEGF response.
- EMA called it the first ocular implant of this kind recommended for approval in the EU, with refills every six months.
- A Phase 3 study in 415 patients showed Susvimo comparable to four-weekly intravitreal ranibizumab for visual and anatomical outcomes.
- Common adverse events included iritis, conjunctival bleb/leak, cataract, vitreous floaters, haemorrhage, hyperaemia, eye pain and headache.
Susvimo at a glance
| Field | Detail |
|---|---|
| Medicine | Susvimo (ranibizumab) + refillable ocular implant |
| Applicant | Roche Registration GmbH |
| Regulator step | CHMP positive opinion (24 July 2026) |
| Population | Adults with nAMD stable after responding to intravitreal anti-VEGF |
| Refill interval | Every six months (per EMA) |
| Key evidence | Phase 3 randomised, assessor-masked study; n=415 |
| Next step | European Commission marketing authorisation decision |
What did the CHMP recommend?
EMA said Susvimo is for adults with neovascular (wet) AMD, used only with a refillable implant surgically inserted into the eye, and only in people whose disease is stable after responding to an intravitreal VEGF inhibitor. Intravitreal ranibizumab has been authorised in the EU since 2007, usually injected about every four weeks—a burden EMA linked to compliance and real-world vision outcomes.
Full agency write-up: EMA's 24 July Susvimo nAMD announcement.
What clinical evidence did EMA cite?
A Phase 3 randomised, visual assessor-masked, active-comparator study in 415 patients with nAMD showed Susvimo comparable to monthly intravitreal ranibizumab for maintaining visual and anatomical outcomes. The port delivery programme includes Archway (NCT03677934) on ClinicalTrials.gov.
- Most common side effects: iritis, conjunctival bleb/filtering bleb leak, cataract, vitreous floaters
- Also listed: conjunctival haemorrhage, conjunctival hyperaemia, eye pain, headache
- Implant designed for continuous release with six-monthly refill
How does this fit the July CHMP agenda?
Susvimo was one of twelve new medicines recommended at the 20–23 July 2026 CHMP meeting, alongside oral lipid and psoriasis firsts. See the full list in EMA's CHMP 20–23 July 2026 meeting highlights.
What happens next?
The opinion goes to the European Commission for an EU-wide marketing authorisation. After that, price and reimbursement decisions sit with each Member State. Roche is the named applicant.
What remains uncertain?
CHMP recommendation is not Commission approval. Surgical implant risks, endophthalmitis rates, and real-world refill logistics will shape uptake. Comparative durability versus treat-and-extend injection regimens beyond the pivotal window needs post-authorisation follow-up.
Related NovaPharma coverage
- EMA Backs Etcamah for ESR1+ Breast Cancer
- Acadia Daybu CHMP OK for Rett syndrome
- CHMP May 2026 Output
Frequently Asked Questions
What did EMA recommend for Susvimo?
On 24 July 2026, EMA's CHMP recommended an EU marketing authorisation for Susvimo (ranibizumab) to treat adults with neovascular (wet) age-related macular degeneration, used only with a surgically inserted refillable ocular implant in people whose disease is stable after responding to intravitreal anti-VEGF therapy.
How often is the Susvimo implant refilled?
EMA said the implant is designed to release ranibizumab over time and is refilled every six months, offering an alternative to typical four-weekly intravitreal ranibizumab injections.
Is Susvimo already authorised in the EU?
Not yet. The CHMP opinion goes to the European Commission for a final EU-wide marketing authorisation decision. Pricing and reimbursement then follow at Member State level. The applicant is Roche Registration GmbH.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Susvimo.
Unlock full calendar →Roche pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
